Travis Scott enters a fever dream in the visual for “4×4.” On Friday, the rapper released the video for the new single, which sees him living different scenarios — from ultra-protected ...

Adults receiving tirzepatide in the SURPASS trials had ... SURPASS trials enrolled adults with type 2 diabetes or overweight or obesity and without contraindications for GIP/GLP-1 use.

today announced the completion of its Phase 2 BMT-801 clinical study of the co-administration of MC4R bremelanotide + GLP-1/GIP tirzepatide for the treatment of obesity. The last patient enrolled ...

BOSTON, MA—Tirzepatide improves outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, no matter how much excess body weight they have, according to an analysis ...

The Senate confirmed Scott Bessent as Treasury secretary on Monday, elevating the hedge fund manager to the new administration’s top financial job as President Donald Trump forges ahead on an ...

According to the GlobalData forecasts, the obesity market can reach up to $ ... drugs on the market are Eli Lilly’s Mounjaro/Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide ...

The surge in anti-obesity drug development has been made possible by the blockbuster success of semaglutide and its rival drug tirzepatide — sold as Zepbound or Mounjaro. These drugs have ...

Weight loss drugs like Ozempic and wegovy have become global sensation. In the recent years, companies like Novo Nordisk and Eli Lilly have GLP-1 agonists and dual GLP-1/GIP receptor agonists that ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

WASHINGTON — The U.S. Senate confirmed billionaire investor Scott Bessent on Monday to serve as President Donald Trump’s treasury secretary, giving him the delicate balancing act of cutting ...

and the dual GLP-1R/GIPR agonist Mounjaro/Zepbound (tirzepatide), capable of promoting body weight loss of up to 25%. The obesity drug development pipeline is vast and includes both incretin ...

on Thursday announced the completion of its Phase 2 BMT-801 clinical study evaluating the combination of MC4R bremelanotide and GLP-1/GIP tirzepatide for the treatment of obesity. The study ...